RxDoctor Payments Data

Rana Munna, MD

Internal Medicine · Macon, GANPI 1053339168

Payments from drug & device makers

$1,490in general payments, 2019–2025

Across 51 payments — averaging $29.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$551
  • Amgen$196
  • Johnson & Johnson$123
  • AbbVie$118
  • Pfizer$109
  • Axsome Therapeutics, Inc.$101
  • plus $292 from 9 others

What the payments were for

  • Food & beverage$1,490100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,490 in reported general payments places this provider in the 70th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$162,709
Medicare patients
317
Services billed
2,336

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban118$97,113
OzempicSemaglutide65$77,554
MounjaroTirzepatide54$62,503
XareltoRivaroxaban34$38,659
JanuviaSitagliptin Phosphate17$23,804
LinzessLinaclotide12$12,538
NamzaricMemantine Hcl/Donepezil Hcl13$7,662
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog25$6,580
Lantus SolostarInsulin Glargine,hum.Rec.Anlog23$4,686
SynthroidLevothyroxine Sodium51$4,472
Nebivolol Hcl56$3,566
Levothyroxine Sodium323$3,456
Bupropion XlBupropion Hcl119$2,791
Rosuvastatin Calcium222$2,705
Losartan Potassium213$2,293

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$109$97,113118 claims
Novo NordiskOzempic$39$77,55465 claims
Lilly USA, LLCMounjaro$57$62,50354 claims
Johnson & JohnsonXarelto$123$38,65934 claims
AbbVieLinzess, Namzaric, Synthroid$118$24,67176 claims
MerckJanuvia$41$23,80417 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Macon

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →